Boehringer Ingelheim acquires ViraTherapeutics for €210m in strategic cancer immunotherapy expansion

German pharmaceutical powerhouse Boehringer Ingelheim has acquired Austria-based oncolytic virus developer ViraTherapeutics for €210 million, cementing its strategic pursuit of innovative, viral-based cancer immunotherapy solutions. ... Read More